Papers/PMID:29670330
The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial.
Drug design, development and therapy2018The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
Ginkgo biloba — no detected effect on total leukocyte count
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The white blood cell count did not change either in the GKB or in the placebo group after 90 days.”
Quoted verbatim from The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial.. - Study
- RCT
- Participants
- 47
- Duration
- 3 months
- Dose
- 120 mg once daily for 90 days, added to ongoing metformin
- Population
- Adults aged 25 to 65 with type 2 diabetes uncontrolled on metformin, recruited in Sulaimani, Iraq; both arms continued their usual metformin dose throughout.
The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial.2018PMID:29670330Permalink